Finance
Samsung Biologics to buy US drug production facility from GSK for $280 million
Published by Global Banking & Finance Review®
Posted on December 21, 2025
1 min readLast updated: January 20, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on December 21, 2025
1 min readLast updated: January 20, 2026
Samsung Biologics is acquiring a US drug facility from GSK for $280M to expand capacity and meet US demand, with the deal closing by Q1 2026.
SEOUL, Dec 22 (Reuters) - South Korea's Samsung Biologics said on Monday it is acquiring its first U.S. drug production facility from GSK for $280 million to respond to long-term U.S. market demand.
The company's U.S. unit, Samsung Biologics America, is acquiring a 100% stake in Human Genome Sciences Inc of Rockville, Maryland, the South Korean contract drug manufacturer said in a statement.
Samsung Biologics plans additional investments to expand the site's capacity, currently a combined 60,000 liters of drug substance capacity, and to upgrade technology, it said.
It added that the acquisition value may change when the deal closes, likely around the end of the first quarter of 2026.
South Korea's Celltrion is also planning to produce drugs in the United States, where the Trump administration has threatened to levy tariffs on pharmaceuticals.
Under a deal with the United States, tariffs on U.S. imports of South Korean pharmaceuticals will be no greater than 15%, while generic drugs will be tariff-free.
Samsung Biologics shares were down 0.4% on Monday, lagging the wider market's 2% gain.
(Reporting by Joyce Lee and Hyunjoo Jin; Editing by Diane Craft and Edmund Klamann)
An acquisition is a corporate action in which one company purchases most or all of another company's shares to gain control of that company.
Biotechnology is a field that uses biological systems, living organisms, or derivatives to develop or create products, often in pharmaceuticals and agriculture.
Market demand refers to the total quantity of a product or service that consumers are willing and able to purchase at a given price over a specific period.
Drug production capacity is the maximum amount of pharmaceutical products that a manufacturing facility can produce within a specific timeframe.
Explore more articles in the Finance category
